ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 255,01
0,58%
Dow Jones
44 296,51
0,97%
DAX
19 322,59
0,91%
Brent Oil
74,65
0,00%
Bitcoin
97 863,51
0,08%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. GlycoMimetics Inc (GLYC)

  7. GlycoMimetics Inc (GLYC) Actualités

GLYC

GlycoMimetics (GLYC)

GlycoMimetics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GLYC
DateHeureSourceTitreSymboleSociété
12/11/202414h00PR Newswire (US)Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024NASDAQ:GLYCGlycoMimetics Inc
07/11/202422h47Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GLYCGlycoMimetics Inc
07/11/202422h42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
06/11/202423h41Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLYCGlycoMimetics Inc
06/11/202413h00Business WireGlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual MeetingNASDAQ:GLYCGlycoMimetics Inc
04/11/202422h26Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GLYCGlycoMimetics Inc
04/11/202420h01Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLYCGlycoMimetics Inc
29/10/202415h00AllPennyStocks.comShares of Biotech Company Up Over 100% Premarket Following Merger & Funding AnnouncementNASDAQ:GLYCGlycoMimetics Inc
29/10/202415h00AllPennyStocks.comBiotech Up Over +100% Premarket Following Merger And Funding AnnouncementNASDAQ:GLYCGlycoMimetics Inc
29/10/202412h00Business WireGlycoMimetics Enters Into Acquisition Agreement With Crescent BiopharmaNASDAQ:GLYCGlycoMimetics Inc
29/10/202411h30Business WireGlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary EndpointNASDAQ:GLYCGlycoMimetics Inc
15/08/202423h01Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLYCGlycoMimetics Inc
14/08/202422h13Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLYCGlycoMimetics Inc
08/08/202422h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLYCGlycoMimetics Inc
25/07/202415h00Business WireGlycoMimetics Announces Strategic Review and Corporate Restructuring PlanNASDAQ:GLYCGlycoMimetics Inc
04/06/202413h00Business WireGlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
29/05/202422h01Business WireGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024NASDAQ:GLYCGlycoMimetics Inc
06/05/202412h00Business WireGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
25/04/202413h00Business WireGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:GLYCGlycoMimetics Inc
27/03/202412h00Business WireGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023NASDAQ:GLYCGlycoMimetics Inc
13/03/202412h00Business WireGlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024NASDAQ:GLYCGlycoMimetics Inc
26/02/202413h00Business WireGlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceNASDAQ:GLYCGlycoMimetics Inc
12/02/202413h00Business WireGlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:GLYCGlycoMimetics Inc
17/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
04/01/202413h00Business WireGlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687NASDAQ:GLYCGlycoMimetics Inc
03/01/202413h00GlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
10/12/202318h00Business WireGlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
09/11/202313h00Business WireGlycoMimetics to Participate in Upcoming Jefferies London Healthcare ConferenceNASDAQ:GLYCGlycoMimetics Inc
03/11/202312h00Business WireGlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023NASDAQ:GLYCGlycoMimetics Inc
23/10/202314h30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:GLYCGlycoMimetics Inc
 Showing the most relevant articles for your search:NASDAQ:GLYC

Dernières Valeurs Consultées

EU
PX1
CAC 40
EU
SGO
Cie de SaintGobain
EU
PX4
SBF 120
COIN
ETHUSD
Ethereum
EU
RI
Pernod Ricard
NASDAQ
GOOGL
Alphabet
NYSE
MRK
Merck
COIN
XRPUSD
Ripple
NASDAQ
AAPL
Apple
NASDAQ
AMZN
Amazon.com
EU
ACA
Credit Agricole
NYSE
MCD
McDonalds
EU
LR
Legrand
EU
BNP
BNP Paribas
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés

BLACK FRIDAY

ADVFN

Célébrons nos 25 ans Est 1999-2024

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Cours Euronext en temps réel et illimités sur le site. Carnet d'ordres Euronext en direct